Drug Trial Radar · NCT06592417
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Apr 30, 2024
Primary completion
May 17, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
Conditions
- Advanced Malignant Solid Tumor
Interventions
JSKN016 injectionDrug
JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTsTime frame: 21 days after the first dose for subjects at dose escalation stage
- The frequency and severity of treatment-related adverse events (TEAE), treatment-related adverse events (TRAE), and serious adverse events (SAE).Time frame: From first dose to 30 days after last dose
- MTD or RP2D of JSKN 016Time frame: Postdose of last participant up to 1 year
- Objective Response Rate (ORR) in Extended queueTime frame: Postdose of last participant up to 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.